multiple%20sclerosis
MULTIPLE SCLEROSIS
Multiple sclerosis is an acquired chronic immune-mediated inflammatory disease of the brain and the spinal cord characterized by presence of multiple discrete areas of myelin loss within the CNS and subsequent axonal degeneration.
Affects more women than man; however, men are more likely to have a malignant clinical course.
A multiple sclerosis attack is usually characterized by any neurological disturbance with minimum 24 hours duration, in the absence of fever or infection.

Introduction

  • Multiple sclerosis is an acquired chronic immune-mediated inflammatory disease of the brain and the spinal cord characterized by presence of multiple discrete areas of myelin loss within the central nervous system and subsequent axonal degeneration
  • A multiple sclerosis attack is usually characterized by any neurological disturbance listed below with minimum of 24 hours duration, in the absence of fever or infection
    • Attack can be either current or historical
    • May occur 30 days between each attack

 

Epidemiology

  • An estimated 2-2.5 million people worldwide have multiple sclerosis
  • In temperate areas (eg United States of America, Canada, New Zealand and parts of Australia), prevalence of multiple sclerosis is >100-200/100,000
  • In tropical areas like in Asia the prevalence of multiple sclerosis is <5/100,000
    • In China the reported prevalence is 1-2/100,000 while in Japan it is 7.7/100,000
    • In Malaysia, the prevalence is estimated range of 2-3/100,000
    • In India, the prevalence is 7.8/100,000
  • Worldwide, multiple sclerosis is more common in women ages 20-40 years old
    • Common among whites than blacks, although blacks appear to become disabled earlier, suggesting more destructive tissue injury in blacks
    • Female to male ratio varies from 2:1 to 3:8

Pathophysiology

  • Multiple sclerosis is characterized by two phases which are the early predominantly inflammatory phase wherein relapses are common and a later more progressive neurodegenerative phase characterized by axonal loss
  • Pathological hallmark of multiple sclerosis is the presence of plaques or lesions which are multiple discrete areas of demyelination in the central nervous system with affinity for the optic nerves, spinal cord, brainstem, cerebellum, juxtacortical, subcortical and periventricular white matter regions as well as the cortical grey matter
  • In early phase of  multiple sclerosis, there is demyelination with inflammation and relative axonal preservation though axon loss also occurs
  • Lesions evolve differently in the early stages than at the later stage of the disease
  • Histologically, there are evidence of inflammation, myelin breakdown, astrogliosis, olidendrocyte injury axonal loss and remyelination
  • In progressive multiple sclerosis, there are increasing axonal loss, neurodegeneration and failure of remyelination
  • As multiple sclerosis is an autoimmune disease, autoreactive T and B cells are activated in the periphery and trans-migrate to the blood-brain barrier triggering an autoimmune cascade which leads to damage of the myelin sheath and axons directly within the central nervous system

Risk Factors

  • Risk factors include:
    • Genetics
    • Ethnicity
    • Sex
      • Affects more women than men; however, men are more likely to have a malignant clinical course
    • Migration and latitude
    • Environmental factors:
      • Not enough exposure to sunlight and ultraviolet radiation
      • Low serum level of 25 hydroxycholecalciferol
      • Infection of Epstein-Barr virus
      • Smoking

Signs and Symptoms

  • Fatigue
  • Nystagmus
  • Optic neuritis
  • Internuclear ophthalmoplegia
  • Vertigo
  • Sensory loss
    • Usually in the lower extremities and trunk
  • Trigeminal neuralgia
  • Lhermitte’s sign
  • Weakness
  • Loss of balance
  • Increased deep tendon reflex
  • Spasticity
  • Bladder dysfunction
  • Sexual dysfunction
  • Constipation
  • Uhthoff phenomenon
  • Depression
Editor's Recommendations
Most Read Articles
Stephen Padilla, 2 days ago
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Pearl Toh, 5 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
15 Jun 2018
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
Jairia Dela Cruz, 2 days ago
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.